Cannabis Users Have 16 Percent Lower Insulin and Smaller Waists

They eat more calories but have smaller waistlines.

Cannabis users eat more calories than non-users. That has been documented repeatedly. They consume more carbohydrates, more protein, and more total energy. By every conventional metric, they should be heavier.

They are not.

A landmark study of 4,657 adults from the National Health and Nutrition Examination Survey found that current cannabis users had 16 percent lower fasting insulin levels, 17 percent lower insulin resistance, and significantly smaller waist circumferences than people who had never used cannabis. These findings held even after adjusting for age, sex, race, education, income, alcohol use, tobacco use, and physical activity. They held after excluding subjects already diagnosed with diabetes.

Cannabis users eat more but weigh less. Their insulin works better. Their metabolic profiles are healthier. And a cannabinoid most people have never heard of -- THCV -- is emerging as one of the most promising therapeutic candidates for type 2 diabetes in modern pharmacology.

Two days to 4/20. This is what rising above the stigma sounds like when the data does the talking.

The NHANES Study: 4,657 Adults

The study, published in The American Journal of Medicine, analyzed data from NHANES collected between 2005 and 2010. Of the 4,657 participants, 579 were current cannabis users, 1,975 were past users, and 2,103 had never used cannabis.

After a nine-hour fast, blood samples measured fasting insulin, fasting glucose, and insulin resistance using the HOMA-IR model -- the standard clinical assessment for how well the body's cells respond to insulin.

The results were unambiguous. Current cannabis users showed 16 percent lower fasting insulin levels and 17 percent lower insulin resistance compared to never-users. They had significantly smaller waist circumferences -- a measurement directly linked to diabetes risk. They also had higher levels of HDL cholesterol, the protective form.

Past users showed weaker but still present associations, suggesting that the metabolic benefits are strongest during active use and fade over time.

Lead researcher Dr. Murray Mittleman of the Cardiovascular Epidemiology Research Unit at Beth Israel Deaconess Medical Center noted that the findings remained statistically significant even after excluding subjects with diabetes, ruling out the possibility that diabetic patients had simply stopped using cannabis. The relationship between cannabis use and favorable metabolic indices was real and independent of disease status.

The paradox -- more calories, less fat, better insulin function -- suggests that the endocannabinoid system plays a direct role in metabolic regulation that goes beyond simple calorie accounting.

THCV: The Cannabinoid That Fights Diabetes

If the NHANES data provides the population-level signal, THCV provides the molecular explanation.

Tetrahydrocannabivarin is a minor cannabinoid found in certain cannabis cultivars, primarily African sativas. Unlike THC, which activates the CB1 receptor and stimulates appetite, THCV antagonizes CB1 -- meaning it blocks the receptor. This gives THCV the opposite metabolic profile from THC: it suppresses appetite, increases energy expenditure, and improves insulin signaling.

A 2016 randomized controlled trial published in Diabetes Care tested THCV in 62 patients with type 2 diabetes who were not taking insulin. The results were clinically significant.

THCV reduced fasting plasma glucose from 7.4 to 6.7 mmol/L, while the placebo group saw their glucose rise from 7.6 to 8.0 mmol/L. THCV improved beta-cell function as measured by HOMA2, meaning the pancreatic cells that produce insulin were working better. THCV increased adiponectin concentrations -- a protein that enhances liver insulin sensitivity, increases fatty acid oxidation, and has important anti-atherosclerotic properties.

Notably, CBD alone did not produce these glycemic improvements. THCV was the active player.

In preclinical studies, THCV enhanced the response of Akt -- a key protein in the insulin signaling cascade -- to insulin in insulin-resistant human liver cells. This suggests THCV may directly restore insulin signaling at the cellular level, not just reduce glucose through downstream effects.

A comprehensive 2025 review published in AIMS Neuroscience summarized the evidence: THCV enhances insulin sensitivity, promotes glucose uptake in peripheral tissues, reduces lipid accumulation in fat cells and liver cells, improves mitochondrial activity, and suppresses appetite-driven hyperglycemia through CB1 antagonism while improving insulin sensitivity through CB2 partial activation. The review concluded that THCV represents "a novel therapeutic candidate for type 2 diabetes management."

GW Pharmaceuticals, the company behind the FDA-approved CBD medication Epidiolex, is currently developing a THCV-based medication specifically targeting diabetes.

The Metabolic Paradox Explained

Why do cannabis users eat more but weigh less? The endocannabinoid system provides the answer.

The CB1 receptor is a master regulator of energy balance. When chronically overstimulated -- as it is in obesity and metabolic syndrome -- the system becomes dysregulated. Peripheral CB1 receptors in fat tissue, liver, and muscle promote fat storage, insulin resistance, and inflammation.

Cannabis use, particularly over time, appears to downregulate CB1 receptor density and sensitivity. This is the body adapting to regular cannabinoid exposure by reducing the number and responsiveness of the receptors that drive metabolic dysfunction. The result is paradoxical: exposure to cannabinoids leads to a system that behaves as if it has fewer active CB1 receptors, which is exactly what you want for metabolic health.

This is supported by the THCV data. THCV actively blocks CB1 -- it is a pharmacological CB1 antagonist. The metabolic benefits of THCV mirror what happens when the endocannabinoid system is dialed down: less appetite drive, better insulin sensitivity, lower fat storage, more energy expenditure.

The pharmaceutical industry tried this approach once before with rimonabant, a synthetic CB1 blocker that was approved in Europe for obesity. It worked for weight loss but caused severe psychiatric side effects including depression and suicidal ideation. It was pulled from the market. THCV appears to achieve similar metabolic benefits without the psychiatric risks, likely because it is a partial antagonist rather than a full blocker, and because it also activates CB2 receptors which have anti-inflammatory and mood-stabilizing effects.

The Honest Limitations



The NHANES study is observational. It shows correlation, not causation. It is possible that people who use cannabis are different from non-users in ways the study did not measure -- lifestyle factors, stress levels, dietary choices beyond total calories -- that explain the metabolic advantages.

The THCV human trial involved only 62 patients over a relatively short period. Larger, longer trials are needed to confirm the glycemic benefits and establish optimal dosing. Most cannabis products on the market contain minimal THCV because it is present in low concentrations in most cultivars and is expensive to isolate or breed for.

And the relationship between cannabis and appetite is complex. THC stimulates appetite through CB1 activation, which could theoretically worsen glycemic control in some patients. The metabolic benefits may depend heavily on which cannabinoids are present, their ratios, and the duration of use.

For the 37 million Americans living with diabetes and the 96 million with prediabetes, this research opens a door. But it is a door that leads to more questions, not a finished room. Rising above the stigma means presenting the evidence as it is -- promising, incomplete, and worth pursuing.